Search results
-
ASCO 2025 – BioNTech shows promise in mesothelioma
ASCO 2025 – BioNTech shows promise in mesothelioma … pts) Note: *investigator-sponsored trial. Source: ASCO 2025. Still, BioNTech's data came from just 31 …
- 05/19/2026 - 19:49 -
ASCO 2025 – an early split between PD-L1 conjugates
ASCO 2025 – an early split between PD-L1 conjugates …
- 05/19/2026 - 19:49 -
ASCO 2025 – Amgen gets one over on Zai Lab
ASCO 2025 – Amgen gets one over on Zai Lab …
- 05/19/2026 - 19:49 -
ASCO 2025 – Astellas's new Claudin18.2 interest
ASCO 2025 – Astellas's new Claudin18.2 interest …
- 05/19/2026 - 19:49 -
ASCO 2025 – Lilly makes a folate foray against Genmab
ASCO 2025 – Lilly makes a folate foray against Genmab … Trial Ph1 Ph1/2 Rainfol-01 Venue ASCO 2025 SGO 2025 Cutoff 9 March 2025 15 … *4mg/kg Q3W dose only; **120mg/m2 Q3W dose only. Source: ASCO 2025. The patients in the LY4170156 trial …
- 05/19/2026 - 19:49 -
ASCO 2025 – BioNTech has a prostate decision to make
ASCO 2025 – BioNTech has a prostate decision to make …
- 05/19/2026 - 19:49 -
ASCO 2025 – J&J takes another prostate cancer shot
ASCO 2025 – J&J takes another prostate cancer shot … 4-8 only; ^^RP2D only; ^^^across whole trial. Source: ASCO 2025, OncologyPipeline & company presentations. …
- 05/19/2026 - 19:49 -
ASCO 2025 – Bicara's ficerafusp claim turns to PD-L1 status
ASCO 2025 – Bicara's ficerafusp claim turns to PD-L1 …
- 05/19/2026 - 19:49 -
ASCO 2025 – Astra "looked at" patritumab but passed
ASCO 2025 – Astra "looked at" patritumab but passed …
- 05/19/2026 - 19:49 -
ASCO 2025 – Dizal goes after the BTK leaders
ASCO 2025 – Dizal goes after the BTK leaders …
- 05/19/2026 - 19:49
